Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Development and evaluation of Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases.

Descrizione del progetto

Farmaci intelligenti per il trattamento delle patologie infiammatorie

Le specie reattive dell’ossigeno (ROS, reactive oxygen species), molecole altamente reattive contenenti ossigeno, emergono come sottoprodotti naturali del normale metabolismo di questo elemento; sebbene esse siano coinvolte nella segnalazione e nell’omeostasi cellulare, possono danneggiare il DNA e altre macromolecole, causando disfunzioni nelle cellule e stress ossidativo. Finanziato dal programma di azioni Marie Skłodowska-Curie, il progetto ROSCURE-O2 propone un modo inteso ad esplorare i livelli di ROS endogene per la somministrazione di farmaci antinfiammatori. I ricercatori svilupperanno un sistema intelligente di somministrazione controllata dei farmaci basato su nanoparticelle che eliminano i livelli di ROS nei tessuti infiammati, offrendo un approccio innovativo per il trattamento di condizioni infiammatorie come le lesioni cutanee indotte dalle radiazioni.

Obiettivo

The evolving landscape of medical research demands innovative breakthroughs to enhance disease treatments. Smart drug delivery systems (DDS) are at the forefront of these innovations, offering precise drug release while combatting oxidative stress and harmful species. ROSCURE-O2 (Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases), is a pioneering proposal focusing on engineering ROS-responsive DDS with anti-inflammatory and anti-hypoxia properties.Inflammation profoundly affects global health, contributing to various skin and wound conditions, including radiation-induced skin injuries (RISI). RISI arises from healthy cells' exposure to ionizing radiation used in cancer radiotherapy, leading to issues ranging from mild skin reactions to severe burns, ulcers, infections, and necrosis, impacting the quality of life for over 95% of radiotherapy patients.

ROSCURE-O2 aims to develop innovative treatments for inflammatory conditions by targeting ROS and hypoxia precisely. The hypothesis posits that multifunctional DDS can (1) scavenge ROS, (2) selectively release anti-inflammatory drugs, and (3) deliver oxygen in ROS-rich environments, thus preventing and curing inflammatory diseases. This triple therapeutic approach seeks to overcome the limitations of conventional treatments.

Within ROSCURE-O2 the development of a Smart DDS platform that can synergistically address ROS and hypoxia. This involves polymeric DDS with ROS-responsive properties, provided by sulfur-based chemistries and/or antioxidant crosslinkers and the incorporation of oxygen-releasing and ROS-scavenging nanoparticles, like Cerium Oxide. These nanoparticles can be combined with anti-inflammatory active pharmaceutical ingredients to increase treatment efficacy and reduce costs. ROSCURE-O2's outcomes have the potential to advance our understanding of ROS-responsive drug delivery and tissue regeneration through oxygen delivery.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Contributo netto dell'UE
€ 165 312,96
Indirizzo
CALLE SERRANO 117
28006 Madrid
Spagna
Regione
Comunidad de Madrid Comunidad de Madrid Madrid
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato